ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Liquid biopsy start-up Seer launches

by Ryan Cross
January 7, 2019 | APPEARED IN VOLUME 97, ISSUE 1

 

Seer, a diagnostics start-up based in South San Francisco, has launched with $36 million in series A and B financing to develop liquid biopsies for early detection of cancer and neurological diseases. Many companies developing liquid biopsies are focused on using trace pieces of DNA in the blood. Seer is developing proteomics-based biopsies to spot scarce proteins in the blood that could be a signal of disease. CEO Omid Farokhzad cofounded Seer based on his work at Harvard Medical School.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment